查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1628898

骨癌治療市場，按類型、治療、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Bone Cancer Treatment Market, By Type, By Treatment, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年骨癌治療市場規模為13.215億美元，2024年至2032年複合年成長率為5.50%。

骨癌治療市場-市場動態

骨癌發生率上升

由於骨癌發生率上升，預計骨癌治療市場將會擴大。始於骨組織的惡性（癌性）腫瘤稱為骨癌。當骨細胞生長失控並分裂，形成腫瘤或腫塊時，就會發生這種情況。骨癌治療的目的是為患者提供許多好處。這種療法治療了多種骨惡性腫瘤，包括手術、肢體保留、緩解疼痛、改善生活品質和控制腫瘤。例如，代表美國醫生的專業組織美國臨床腫瘤學會（ASCO）於 2023 年 2 月報告稱，美國將診斷出 3,970 例新原發性骨肉瘤病例（2,160 名男性和 1,810 名女性）到2023 年，15至19 歲族群中將有201 例。

骨癌治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球骨癌治療市場在預測期內（2024-2032）每年將以 5.50% 左右的複合年成長率成長

根據類型細分，預計原發性骨癌類別將在 2023 年顯示最大的市場佔有率

從治療細分來看，2023年化療是領先細分領域

按地區分類，北美是 2023 年的主要收入來源

骨癌治療市場-細分分析：

全球骨癌治療市場根據類型、治療、最終用戶和地區進行細分。

根據類型，市場分為原發性骨癌（尤文氏肉瘤、骨肉瘤、軟骨肉瘤、其他原發性骨癌）和繼發性骨癌。原發性骨癌類別在 2023 年引領市場。這與從身體其他部位擴散的骨癌（通常稱為繼發性或轉移性骨癌）不同。原發性骨癌通常需要專門的治療方法，包括放射治療、標靶治療和保肢手術。此外，與肺癌或乳癌等其他癌症相比，原發性骨癌相對罕見。然而，它的稀缺性並沒有削弱它的重要性。原發性骨癌因其發病率極低而成為研究和治療開發的焦點。

依治療方法，市場分為標靶治療和免疫治療（狄諾塞麥、舒尼替尼、伊馬替尼、其他標靶和免疫治療）、放射治療、手術和化療（阿黴素、依托泊苷、順鉑、環磷醯胺、其他化療）。 2023年，化療類別成為全球骨癌治療市場的主導力量。化療是一種全身性治療，透過血液傳播到身體的各個部位。這項功能使其能夠針對原始骨腫瘤以及任何可能的轉移或器官擴散中的癌細胞。化療對於減少腫瘤非常有效，即使是位於骨組織等難以到達的地方的腫瘤也是如此。化療對於限制骨癌的生長和擴散非常重要，特別是對於處於疾病晚期或明顯轉移的患者。手術後，化療常用作輔助治療。移除手術後可能殘留的任何癌細胞可以降低原發性骨癌復發的機會。有時在手術前進行新輔助治療或化療。

骨癌治療市場 - 地理洞察

從地理來看，骨癌治療市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

北美骨癌治療市場的特點是其發達的醫療基礎設施、對研發的高度重視以及高醫療保健支出。該地區強力的報銷政策和監管結構鼓勵開發和採用創新的骨癌治療方案。北美許多生技和製藥公司也積極致力於創造骨癌新療法，例如免疫療法、標靶藥物和個人化醫療策略。由於該地區骨癌發病率上升，尤其是老年人口，該市場也在不斷成長。

在整個預測期內，亞太市場預計將以最快的速度成長，為骨癌治療產業的參與者提供顯著的成長前景。亞太地區龐大且不斷成長的人口等因素暗示著龐大的患者群體。預計隨著醫療保健可近性的改善，骨癌治療的需求將會增加。在亞太國家，快速的工業化和生活方式的改變導致癌症病例增加，特別是骨癌。這種趨勢要求骨癌治療市場的成長。該地區龐大且多樣化的患者群體使其成為臨床研究中心。

骨癌治療市場-競爭格局：

骨癌治療市場高度分散，主要是因為許多競爭對手在本地和全球範圍內營運，例如輝瑞、百特國際公司、Advaxis、安進、Atlanthera、拜耳公司等。對市場整體動態做出貢獻的各種公司決定了競爭格局。這種分類是老牌產業參與者、新來者和專業解決方案供應商之間爭奪市場佔有率的結果。利用多種策略來提高公司的知名度凸顯了市場參與者的多樣性。在全球範圍內，所研究行業的企業正在透過積極的擴張計劃將自己置於戰略地位。例如，Zetagen Therapeutics 的 ZetaMet 技術於 2021 年 12 月被美國食品和藥物管理局 (FDA) 設備和放射健康中心 (CDRH) 指定為突破性產品。疾病。這有助於企業加快審查和開發過程。

最新進展：

2024 年 2 月：Telix 宣布有意收購 QSAM Biosciences, Inc. 及其主要實驗藥物 Samarium-153-DOTMP (153Sm-DOTMP)。一家名為 QSAM 的美國公司生產治療原發性骨癌和轉移性骨癌的放射性藥物。透過此次收購，該公司能夠擴大客戶群並打入未開發的市場。

2023年10月：Zetagen Therapeutics在同行評審期刊《疼痛管理》上發布了ZetaMet的初步臨床研究結果。其中包括有關 ZetaMet 對骨轉移患者的有效性和安全性的資訊。

2023 年 3 月：CADD522 是一種新型藥物，由謝菲爾德大學和東安格利亞大學的研究人員創建，用於治療原發性骨惡性腫瘤患者。在臨床前模型中，這種藥物使存活率提高了 50%。

目錄

第1章：骨癌治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的骨癌治療市場片段
    • 骨癌治療市場片段（依治療）
    • 最終用戶的骨癌治療市場片段
    • 按國家/地區分類的骨癌治療市場片段
    • 按地區分類的骨癌治療市場片段
  • 競爭洞察

第 3 章：骨癌治療主要市場趨勢

  • 骨癌治療市場促進因素
    • 市場促進因素的影響分析
  • 骨癌治療市場限制
    • 市場限制影響分析
  • 骨癌治療市場機會
  • 骨癌治療市場未來趨勢

第 4 章：骨癌治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：骨癌治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：骨癌治療市場格局

  • 2023 年骨癌治療市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：骨癌治療市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 原發性骨癌
      • 尤文氏肉瘤
      • 骨肉瘤
      • 軟骨肉瘤
      • 其他原發性骨癌
    • 繼發性骨癌

第 8 章：骨癌治療市場 - 按治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 標靶和免疫治療
      • 狄諾塞麥
      • 舒尼替尼
      • 伊馬替尼
      • 其他標靶和免疫療法
    • 放射治療
    • 手術
    • 化療
      • 阿黴素
      • 依托泊苷
      • 順鉑
      • 環磷醯胺
      • 其他化療

第 9 章：骨癌治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 門診手術中心 (ASC)
    • 腫瘤中心和專科診所
    • 其他

第 10 章：骨癌治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美骨癌治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（以不同處理方式）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲骨癌治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按處理方式）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區骨癌治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（以不同處理方式）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲骨癌治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（以不同處理方式）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲骨癌治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東及非洲市場規模及預測（依不同處理方式）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 骨癌治療產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • Baxter International Inc.
    • Advaxis Inc.
    • Amgen Inc.
    • Atlanthera
    • Bayer AG
    • Debiopharm
    • Spectrum Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company
    • Johnson & Johnson
    • Gradalis Inc.
    • Eli Lilly and Company
    • Hikma Pharmaceutical PLC
    • Novartis AG
    • Recordati Group
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4431

REPORT HIGHLIGHT

Bone Cancer Treatment Market size was valued at USD 1,321.5 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

When aberrant cells in bone grow out of control, bone cancer occurs. Healthy bone tissue is destroyed in this cancer. Malignant or cancerous bone tumours can occur. Cancer cells can spread throughout the body as a result of malignant bone tumours. Children, teens, and young adults are more likely to experience them than older adults; however, they can appear at any age. Bone cancer can be treated with a variety of methods, including surgery, radiation therapy, chemotherapy, and targeted therapy. The rise in cancer prevalence, the expansion of government efforts, and the spike in product launches and approvals are the main drivers propelling the growth of the bone cancer treatment market. Moreover, a key driver of the market for bone cancer treatments is the rise in bone cancer, particularly osteosarcoma.

Bone Cancer Treatment Market- Market Dynamics

Rising Incidence of Bone Cancer

It is anticipated that the market for bone cancer treatments will expand due to the rising incidence of bone cancer. Malignant (cancerous) tumours that start in bone tissue are referred to as bone cancer. It happens when bone cells grow out of control and divide, creating a tumour or mass. The purpose of bone cancer treatments is to provide patients with a number of benefits. Several bone malignancies were treated with this therapy, which included surgery, limb preservation, pain relief, improved quality of life, and tumour control. For instance, the American Society of Clinical Oncology (ASCO), a professional organization that represents physicians in the United States, reported in February 2023 that 3,970 new cases of primary bone sarcoma (2,160 men and 1,810 women) would be diagnosed in the United States in 2023, out of 201 cases in people aged 15 to 19. Thus, the market for bone cancer treatments is being driven by the rising incidence of bone cancer.

Bone Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global Bone Cancer Treatment Market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on type segmentation, the primary bone cancer category was predicted to show maximum market share in the year 2023

Based on treatment segmentation, chemotherapy was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Bone Cancer Treatment Market- Segmentation Analysis:

The Global Bone Cancer Treatment Market is segmented on the basis of Type, Treatment, End-user, and Region.

Based on type, the market is categorized into Primary bone cancer (Ewing sarcoma, Osteosarcoma, Chondrosarcoma, Other primary bone cancer) and Secondary bone cancer. The primary bone cancer category led the market in 2023. Primary bone cancer, sometimes referred to as bone sarcoma, is cancer that starts in the bone and does not spread to other organs. This distinguishes it from bone cancer that has spread from other parts of the body, often known as secondary or metastatic bone cancer. Specialized treatment approaches, including radiation therapy, targeted therapies, and limb-sparing procedures, are usually required for primary bone cancer. In addition, compared to other cancers like lung or breast cancer, primary bone cancer is comparatively uncommon. Its scarcity does not, however, lessen its significance. Primary bone cancer is a focus of study and therapeutic development due to its very low incidence.

By treatment, the market is segregated into Targeted and immunotherapy (Denosumab, Sunitinib, Imatinib, Other targeted & immunotherapies), Radiation therapy, Surgery, and Chemotherapy (Doxorubicin, Etoposide, Cisplatin, Cyclophosphamide, Other chemotherapies). In 2023, the chemotherapy category became the leading force in the global market for the treatment of bone cancer. Chemotherapy is a systemic treatment that travels through the bloodstream to all parts of the body. This feature enables it to target cancer cells in the original bone tumour as well as any possible metastases or organ spreads. Chemotherapy works very well in reducing tumours, even ones that are located in difficult-to-reach places like bone tissue. Chemotherapy can be extremely important in limiting the growth and spread of bone cancer, particularly in patients with advanced stages of the illness or significant metastases. Following surgery, chemotherapy is frequently used as an adjuvant treatment. Removing any cancer cells that may have remained after surgery lowers the chance of recurrence in cases of primary bone cancer. Neoadjuvant treatment, or chemotherapy, is sometimes given prior to surgery.

Bone Cancer Treatment Market- Geographical Insights

Geographically, the Bone Cancer Treatment Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for bone cancer treatments in North America is distinguished by its well-developed healthcare infrastructure, substantial emphasis on research and development, and high healthcare spending. Innovative bone cancer treatment options are encouraged to be developed and adopted by the region's strong reimbursement policies and regulatory structure. Many biotechnology and pharmaceutical companies in North America are also actively working on creating new treatments for bone cancer, such as immunotherapies, targeted medicines, and personalized medicine strategies. The market is also growing as a result of the region's rising incidence of bone cancer, especially among the elderly population.

Throughout the projected period, the Asia-Pacific market is expected to grow at the quickest rate, providing participants in the bone cancer treatment industry with significant growth prospects. A significant patient pool is implied by factors like the Asia-Pacific region's enormous and expanding population. It is anticipated that the need for bone cancer treatment will rise as access to healthcare improves. In Asia-Pacific nations, rapid industrialization and changes in lifestyle are causing a rise in cancer cases, particularly bone cancer. This tendency calls for the market for bone cancer treatments to grow. The region's sizable and varied patient population is making it a centre for clinical studies.

Bone Cancer Treatment Market- Competitive Landscape:

The bone cancer treatment market is highly fragmented, mainly because many competitors are operating both locally and globally, such as Pfizer Inc., Baxter International Inc., Advaxis Inc., Amgen Inc., Atlanthera, Bayer AG, and others. Various companies that all contribute to the overall dynamics of the market defines the competitive landscape. This division results from the competition for market share between established industry players, newcomers, and specialist solution suppliers. The use of a variety of tactics to increase the company's visibility highlights the diversity of market players. Globally, businesses in the industry under study are putting themselves in a strategic position by pursuing aggressive expansion plans. For instance, Zetagen Therapeutics' ZetaMet technology was designated a breakthrough product by the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) in December 2021. It demonstrates ZetaMet's promise as a cutting-edge therapy for metastatic bone diseases. This aided the business in accelerating the review and development process.

Recent Developments:

February 2024: Telix declared its intention to purchase QSAM Biosciences, Inc. and its primary experimental medication, Samarium-153-DOTMP (153Sm-DOTMP). A U.S.-based business called QSAM creates therapeutic radiopharmaceuticals for bone cancer, both primary and metastatic. The company was able to expand its clientele and break into unexplored markets thanks to this acquisition.

October 2023: Zetagen Therapeutics released ZetaMet's preliminary clinical study results in the peer-reviewed journal Pain Management. This includes information on ZetaMet's effectiveness and safety in patients with bone metastases.

March 2023: CADD522, a novel medication, was created by researchers at the Universities of Sheffield and East Anglia to treat patients with primary bone malignancies. In preclinical models, this medication increased survival rates by 50%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BONE CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Baxter International Inc.
  • Advaxis Inc.
  • Amgen Inc.
  • Atlanthera
  • Bayer AG
  • Debiopharm
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company
  • Johnson & Johnson
  • Gradalis Inc.
  • Eli Lilly and Company
  • Hikma Pharmaceutical PLC
  • Novartis AG
  • Recordati Group
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Primary bone cancer
  • Ewing sarcoma
  • Osteosarcoma
  • Chondrosarcoma
  • Other primary bone cancer
  • Secondary bone cancer

GLOBAL BONE CANCER TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Targeted and immunotherapy
  • Denosumab
  • Sunitinib
  • Imatinib
  • Other targeted & immunotherapies
  • Radiation therapy
  • Surgery
  • Chemotherapy
  • Doxorubicin
  • Etoposide
  • Cisplatin
  • Cyclophosphamide
  • Other chemotherapies

GLOBAL BONE CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory surgical centers (ASCs)
  • Oncology centers & specialty clinics
  • Others

GLOBAL BONE CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bone Cancer Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bone Cancer Treatment Market Snippet by Type
    • 2.1.2. Bone Cancer Treatment Market Snippet by Treatment
    • 2.1.3. Bone Cancer Treatment Market Snippet by End-user
    • 2.1.4. Bone Cancer Treatment Market Snippet by Country
    • 2.1.5. Bone Cancer Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Bone Cancer Treatment Key Market Trends

  • 3.1. Bone Cancer Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bone Cancer Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bone Cancer Treatment Market Opportunities
  • 3.4. Bone Cancer Treatment Market Future Trends

4. Bone Cancer Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bone Cancer Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bone Cancer Treatment Market Landscape

  • 6.1. Bone Cancer Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bone Cancer Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Primary bone cancer
      • 7.1.2.1. Ewing sarcoma
      • 7.1.2.2. Osteosarcoma
      • 7.1.2.3. Chondrosarcoma
      • 7.1.2.4. Other primary bone cancer
    • 7.1.3. Secondary bone cancer

8. Bone Cancer Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Targeted and immunotherapy
      • 8.1.2.1. Denosumab
      • 8.1.2.2. Sunitinib
      • 8.1.2.3. Imatinib
      • 8.1.2.4. Other targeted & immunotherapies
    • 8.1.3. Radiation therapy
    • 8.1.4. Surgery
    • 8.1.5. Chemotherapy
      • 8.1.5.1. Doxorubicin
      • 8.1.5.2. Etoposide
      • 8.1.5.3. Cisplatin
      • 8.1.5.4. Cyclophosphamide
      • 8.1.5.5. Other chemotherapies

9. Bone Cancer Treatment Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Ambulatory surgical centers (ASCs)
    • 9.1.4. Oncology centers & specialty clinics
    • 9.1.5. Others

10. Bone Cancer Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bone Cancer Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bone Cancer Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bone Cancer Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bone Cancer Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bone Cancer Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bone Cancer Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Baxter International Inc.
    • 11.2.3. Advaxis Inc.
    • 11.2.4. Amgen Inc.
    • 11.2.5. Atlanthera
    • 11.2.6. Bayer AG
    • 11.2.7. Debiopharm
    • 11.2.8. Spectrum Pharmaceuticals Inc.
    • 11.2.9. Takeda Pharmaceutical Company
    • 11.2.10. Johnson & Johnson
    • 11.2.11. Gradalis Inc.
    • 11.2.12. Eli Lilly and Company
    • 11.2.13. Hikma Pharmaceutical PLC
    • 11.2.14. Novartis AG
    • 11.2.15. Recordati Group
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us